The GMO U.S. Quality ETF (QLTY) is currently rated as a Hold due to its mild underperformance compared to the broader market (IVV) since the start of the year. Despite improvements in growth and GARP traits within its IT-heavy portfolio, QLTY's higher PEG ratio suggests a neutral outlook. However, its strong quality screening makes it a viable option for investors focused on quality stocks. The ETF is expected to continue lagging the market until at least 2027, with no clear catalyst for a strong bullish trend.
The U.S. SEC has approved Evernorth's registration, clearing the way for its $1 billion Nasdaq listing under the ticker XRPN through a merger with Armada Acquisition Corp. II. Evernorth plans to actively manage its XRP treasury to generate yield and ...
Amprius Technologies is benefiting from strong demand for drone batteries, reporting a 125.7% year-over-year revenue increase and improved gross margins. The company raised its 2026 revenue forecast to at least $140 million and aims for $600 million ...
INmune Bio is considered significantly undervalued with its treatment Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) driving a strong investment case. Ebstrocel offers systemic itch reduction, setting it apart from competitors like K...
PayPal's stock dropped sharply by 14.67% to $52.45 after Stripe and Advent withdrew their $60.50 per share acquisition offer, causing the company's market value to fall from $52.58 billion to $44.87 billion. This reversal ended the summer rally drive...
SEI Investments Company reported robust Q2 2026 results, exceeding expectations with a 38% increase in adjusted EPS and 36% growth in operating income, driven by strong performance in alternative and private equity markets. The company benefits from ...
